Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00140075 · ClinicalTrials.gov registry record · Phase 3
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
A Phase 3 study of Adenocarcinoma, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 606
- Enrollment target
- 20
- Study locations
NCT00140075: Completed Phase 3 study of Adenocarcinoma, sponsored by Pfizer.
NCT00140075 is a Phase 3 study of Adenocarcinoma that has completed, run by Pfizer. The registered enrollment target is 606 participants, above the 73-participant average among 26 other Adenocarcinoma trials with a reported enrollment target (730% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00140075, a Phase 3 study of Adenocarcinoma, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 606 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare two combinations of drugs, epirubicin given with a taxane (ET) or epirubicin given with cyclophosphamide (cytoxan) and followed by a taxane to see if one of the combinations is better at preventing or delaying the time for breast cancer recurrence and death after 3 years. The study will also evaluate the side effects of both treatment combinations.
Conditions Studied
Interventions
- DRUG Epirubicin with Cyclophosphamide, followed by a Taxane
- DRUG Epirubicin with a Taxane
Study Locations (20)
Florida
- Pfizer Investigational Site - Jacksonville
- Pfizer Investigational Site - Jacksonville
- Pfizer Investigational Site - Kissimmee
- Pfizer Investigational Site - Lake Worth
- Pfizer Investigational Site - Lecanto
- Pfizer Investigational Site - Miami
- Pfizer Investigational Site - Miami Shores
- Pfizer Investigational Site - Port Saint Lucie
- Pfizer Investigational Site - Tampa
California
- Pfizer Investigational Site - Bakersfield
- Pfizer Investigational Site - Berkeley
- Pfizer Investigational Site - Fountain Valley
- Pfizer Investigational Site - Fountian Valley
- Pfizer Investigational Site - Gilroy
- Pfizer Investigational Site - Poway
- Pfizer Investigational Site - Soquel
Alabama
- Pfizer Investigational Site - Mobile
Arizona
- Pfizer Investigational Site - Tucson
Colorado
- Pfizer Investigational Site - Colorado Springs
Georgia
- Pfizer Investigational Site - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 606 participants |
| Start Date | 2000-11 |
| Est. Completion | 2006-08 |
| Phase | Phase 3 |
What the finished NCT00140075 record still lists
NCT00140075 is an interventional study that assigns participants to a tested intervention. The registered 606 participants enrollment target is mid-sized for trials with a published cap, above the 73-participant average among 26 other Adenocarcinoma trials with a reported enrollment target (730% higher).
The record links to 1 condition, with Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Epirubicin with Cyclophosphamide, followed by a Taxane is the first listed.
NCT00140075 names 20 study sites across 6 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT00140075 about?
NCT00140075 is a clinical study titled "Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer". The purpose of this study is to compare two combinations of drugs, epirubicin given with a taxane (ET) or epirubicin given with cyclophosphamide (cytoxan) and followed by a taxane to see if one of the combinations is better at preventing or delaying the time for breast cancer recurrence and death af...
What is the current status of trial NCT00140075?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 606 participants. The study started on 2000-11. Estimated completion is 2006-08.
What conditions does trial NCT00140075 study?
This clinical trial studies the following conditions: Adenocarcinoma.
What interventions are being tested in trial NCT00140075?
The interventions under investigation include: Epirubicin with Cyclophosphamide, followed by a Taxane (DRUG), Epirubicin with a Taxane (DRUG).
Who is sponsoring clinical trial NCT00140075?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00140075 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00140075's enrollment target sits among peer trials
606 1st of 26 higher than 26 of 26 other Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
COMPLETED · Phase 3
-
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
RECRUITING · Early Phase 1
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
-
Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
RECRUITING · Phase 1
-
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02342444 · 606 participants · Phase 4
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
- NCT02064673 · 608 participants · Phase 3
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
- NCT06091202 · 608 participants · Phase 3
Tele-Collaborative Outreach to Rural Patients With Chronic Pain
- NCT06098144 · 608 participants · Phase 4
Smoking Cessation Program in the Construction Sector
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia